Cargando…

Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation

BACKGROUND: Atrial fibrillation (AF) is associated with increasing risk of thromboembolic or ischemic stroke. The CHA(2)DS(2)‐VASc score is a well‐established predictor of AF stroke. Patients with AF have an increased risk of stroke if they have diabetes. Use of sodium‐glucose cotransporter‐2 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Sheng‐Nan, Chen, Jien‐Jiun, Huang, Pang‐Shuo, Wu, Cho‐Kai, Wang, Yi‐Chih, Hwang, Juey‐Jen, Tsai, Chia‐Ti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227316/ https://www.ncbi.nlm.nih.gov/pubmed/37183872 http://dx.doi.org/10.1161/JAHA.122.027764

Ejemplares similares

Copy number variation of gasdermin D gene is associated with atrial fibrillation-related thromboembolic stroke
por: Huang, Pang-Shuo, et al.
Publicado: (2023)

CHA2DS2VASc score predicts risk of end stage renal disease in patients with atrial fibrillation: Long-term follow-up study
por: Huang, Pang-Shuo, et al.
Publicado: (2023)

Genome-Wide Copy Number Variation Association Study of Atrial Fibrillation Related Thromboembolic Stroke
por: Hsieh, Chia-Shan, et al.
Publicado: (2019)

Correlation Between CHA(2)DS(2)-VASc Score and Left Atrial Size in Patients With Atrial Fibrillation: A More Than 15-Year Prospective Follow-Up Study
por: Tsai, Chin-Feng, et al.
Publicado: (2021)

Use of nicorandil is associated with increased risk of incident atrial fibrillation
por: Lee, Chien-Chang, et al.
Publicado: (2022)

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation
por: Karamichalakis, Nikolaos, et al.
Publicado: (2022)

Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis
por: Lin, Ting-Tse, et al.
Publicado: (2015)

An artificial intelligence-enabled ECG algorithm for identifying ventricular premature contraction during sinus rhythm
por: Chang, Sheng-Nan, et al.
Publicado: (2022)

Digoxin-amiodarone Combination is Associated With Excess All-cause Mortality in Patients With Atrial Fibrillation
por: Chiang, Jiun-Yang, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction
por: Peng, Xiaodong, et al.
Publicado: (2020)

Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
por: Zhuo, Min, et al.
Publicado: (2022)

First-in-Human Experience of Using a Universal Steerable Sheath in Implanting Left Atrial Appendage Closure Devices
por: Chang, Sheng-Nan, et al.
Publicado: (2022)

An Artificial Intelligence-Enabled ECG Algorithm for the Prediction and Localization of Angiography-Proven Coronary Artery Disease
por: Huang, Pang-Shuo, et al.
Publicado: (2022)

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus
por: Choi, Y, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
por: Ouyang, Xiaolan, et al.
Publicado: (2023)

Genome-wide screening identifies a KCNIP1 copy number variant as a genetic predictor for atrial fibrillation
por: Tsai, Chia-Ti, et al.
Publicado: (2016)

Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials
por: Sfairopoulos, Dimitrios, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
por: Kim, Nam Hoon, et al.
Publicado: (2022)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
por: Hsieh, Cheng-Yang, et al.
Publicado: (2022)

The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor
por: Chan, Yi-Hsin, et al.
Publicado: (2021)

The Gut Microbiome, Seleno-Compounds, and Acute Myocardial Infarction
por: Chiu, Fu-Chun, et al.
Publicado: (2022)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
por: Lui, David Tak Wai, et al.
Publicado: (2023)

THU338 Risks Of Stroke, Its Subtypes And Atrial Fibrillation Associated With Glucagon-like Peptide 1 Receptor Agonists Versus Sodium-glucose Cotransporter 2 Inhibitors: A Real-world Population-based Study In Hong Kong
por: Lui, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0mao8petcfjvvv6gv7qfngtghi